Drug firm Lupin today announced the launch of its Clonidine Hydrochloride extended-release tablets used in treatment of attention deficit hyperactivity disorder in the US market.
The launch of the company's tablets, which are in the strength of 0.1 mg, is after receiving approval from the United States Food and Drug Administration (USFDA), Lupin said in a statement.
The company's product is a generic version of Concordia International Corp's Kapvay tablets, it added.
The tablets are "indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications," Lupin said.
Kapvay tablets had annual sales of approximately USD 66 million in the US, as per IQVIA MAT December 2017 data, it added.
Shares of Lupin today closed at Rs 814.45 per scrip on BSE, up 0.80 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
